anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Over the past two centuries, vaccines have been critical for the prevention of infectious diseases and are considered milestones in the medical and public health history. The World Health Organization estimates that vaccination currently prevents approximately 3.5-5 million deaths annually, attributed to diseases such as diphtheria, tetanus, pertussis, influenza, and measles. Vaccination has been instrumental in eradicating important pathogens, including the smallpox virus and wild poliovirus types 2 and 3. This narrative review offers a detailed journey through the history and advancements in vaccinology, tailored for healthcare workers. It traces pivotal milestones, beginning with the variolation practices in the early 17th century, the development of the first smallpox vaccine, and the continuous evolution and innovation in vaccine development up to the present day. We also briefly review immunological principles underlying vaccination, as well as the main vaccine types, with a special mention of the recently introduced mRNA vaccine technology. Additionally, we discuss the broad benefits of vaccines, including their role in reducing morbidity and mortality, and in fostering socioeconomic development in communities. Finally, we address the issue of vaccine hesitancy and discuss effective strategies to promote vaccine acceptance. Research, collaboration, and the widespread acceptance and use of vaccines are imperative for the continued success of vaccination programs in controlling and ultimately eradicating infectious diseases.
Systems and methods for automated patient anatomy and orientation identification using an artificial intelligence (AI) based deep learning module are provided. The method comprises positioning a subject over a table of a magnetic resonance imaging (MRI) system and wrapping at least one radiofrequency (RF) imaging coil over the subject. The method comprises obtaining a plurality of depth images, color images and infrared images of the subject using a three-dimensional (3D) depth camera and identifying the table boundary of the MRI system using the images obtained by the 3D camera. The method further comprises identifying a location of the subject over the table to determine if the subject is positioned within the table boundary of the MRI system and identifying a plurality of key anatomical points or regions corresponding to a plurality of organs of the subject body. The method further comprises identifying all DICOM orientations of the subject over the table of the MRI system and identifying the coils of the MRI system wrapped around the subject body and determining the orientation of the subject with respect to the coils of the MRI system, hospital gown, and blankets. The method further comprises identifying the anatomical key points occluded by the coils of the MRI system, hospital gown, and blankets to determine accurate positioning of the coils of the MRI system over the subject anatomy for automated landmarking of anatomies and imaging.
The initial dose of Rapamune should be administered as soon as possible after transplantation. It is recommended that Rapamune be taken 4 hours after administration of cyclosporine oral solution (MODIFIED) and or/cyclosporine capsules (MODIFIED) [see Drug Interactions (7.2)].

Frequent Rapamune dose adjustments based on non-steady-state sirolimus concentrations can lead to overdosing or underdosing because sirolimus has a long half-life. Once Rapamune maintenance dose is adjusted, patients should continue on the new maintenance dose for at least 7 to 14 days before further dosage adjustment with concentration monitoring. In most patients, dose adjustments can be based on simple proportion: new Rapamune dose = current dose × (target concentration/current concentration). A loading dose should be considered in addition to a new maintenance dose when it is necessary to increase sirolimus trough concentrations: Rapamune loading dose = 3 × (new maintenance dose - current maintenance dose). The maximum Rapamune dose administered on any day should not exceed 40 mg. If an estimated daily dose exceeds 40 mg due to the addition of a loading dose, the loading dose should be administered over 2 days. Sirolimus trough concentrations should be monitored at least 3 to 4 days after a loading dose(s).

Two milligrams (2 mg) of Rapamune Oral Solution have been demonstrated to be clinically equivalent to 2 mg Rapamune Tablets; hence, at this dose these two formulations are interchangeable. However, it is not known if higher doses of Rapamune Oral Solution are clinically equivalent to higher doses of Rapamune Tablets on a mg-to-mg basis [see Clinical Pharmacology (12.3)].
The present invention provides a composition for improving liver function, which is useful for improving, for example, symptoms of nonalcoholic hepatitis, by using a resorcinol-based fat-and-oil derived from a plant. A resorcinol-derived lipid derived from a plant is used as an active ingredient of a composition for improving liver function. The resorcinol lipid is preferably an alkyl resorcinol. Furthermore, it is preferably derived from a gramineous plant. Furthermore, brans and/or whole grains derived from wheat and/or rye are preferred. The composition for improving liver function is particularly suitable for improving symptoms of nonalcoholic hepatitis.
Diabetes mellitus is a chronic metabolic disease which seriously threatens people's health at present. Although new drugs for the treatment of diabetes continue to emerge, but the effect of diabetes treatment is still not satisfactory. Medical nutrition therapy (nutrition therapy medical, MNT) and exercise therapy are essential measures for prevention and control of diabetes at any stage of the natural course of the disease, especially for the overweight and obese patients with type 2 diabetes. However, at present, the majority of patients could not get the guide from nutrition specialist and sports specialist. In addition, the existing diet programs are often more complex, difficult to implement and adhere to in daily life, and exercise programs are often lack of targeted. In view of this, the Shanghai peak Sports Management Co., Ltd. developed a kind of nutritional meal replacement for weight loss. The nutritional powder has the characteristics of high nutrition, low calorie, low glycemic and strong satiety, and the heat is only 126kcal, and have a good sense of satiety. Studies have shown that 1 times a day with bags of nutritional meal replacement instead of 1 meals for obese people have a role in weight loss. In theory, the meal is also suitable for diabetes patients, especially overweight and obese type 2 diabetes, such as the combination of individual exercise prescription may be better, but there is still a lack of relevant research. In view of this, we proposed a joint sports workers, explore nutritional and individualized exercise prescription intervention on overweight and obese type 2 diabetes mellitus, to explore suitable for China's diabetes lifestyle intervention measures, improve the level of prevention and treatment of diabetes in China.
Patients receive antiandrogen therapy per standard care and axitinib PO BID for 4 months. Patients then undergo radical prostatectomy and pelvic lymph node dissection.
Effective management of chronic kidney disease (CKD), a major health problem worldwide, requires accurate and timely diagnosis, prognosis of progression, assessment of therapeutic efficacy, and, ideally, prediction of drug response. Multiple biomarkers and algorithms for evaluating specific aspects of CKD have been proposed in the literature, many of which are based on a small number of samples. Based on the evidence presented in relevant studies, a comprehensive overview of the different biomarkers applicable for clinical implementation is lacking. This review aims to compile information on the non-invasive diagnostic, prognostic, and predictive biomarkers currently available for the management of CKD and provide guidance on the application of these biomarkers. We specifically focus on biomarkers that have demonstrated added value in prospective studies or those based on prospectively collected samples including at least 100 subjects. Published data demonstrate that several valid non-invasive biomarkers of potential value in the management of CKD are currently available.
The invention belongs to the technical field of medicines, particularly relating to a traditional Chinese medicine composition for treating gastrointestinal dysfunction of a patient suffering from intra-abdominal hypertension caused by dietetic stagnation. The traditional Chinese medicine composition comprises the following traditional Chinese medicines in parts by weight: 4-8 parts of Chinese fevervine herb and root, 4-8 parts of Phymatopsis crenato-pinnata(C.B.Clarke)Ching(Polypodium crenato-pinnatum C.B.Clarke), 4-8 parts of mandarin pip, 4-8 parts of longan seeds, 4-8 parts of flowers of Japanese banana, 4-8 parts of Vernonia squarrosa (D. Don) Less. (Acilepis squarrosa D. Don; Vernonia teres Mall. Ex DC.) and 4-8 parts of radix glycyrrhizae. The traditional Chinese medicines have effects of promoting digestion and purgation, and promoting the circulation of qi and abating distension or fullness; pressure in the abdominal cavity of the patient suffering from intra-abdominal hypertension can be reduced obviously; and the gastrointestinal dysfunction is relieved.
RITUXAN HYCELA is for subcutaneous use only. RITUXAN HYCELA should only be administered by a healthcare professional with appropriate medical support to manage severe reactions that can be fatal if they occur.

All patients must first receive at least one full dose of a rituximab product by intravenous infusion without experiencing severe adverse reactions before starting treatment with RITUXAN HYCELA. If patients are not able to receive one full dose by intravenous infusion, they should continue subsequent cycles with a rituximab product by intravenous infusion and not switch to RITUXAN HYCELA until a full intravenous dose is successfully administered [see Warnings and Precautions (5.4)].

Refer to the prescribing information for a rituximab product for intravenous infusion for additional information.

Premedicate before each dose of RITUXAN HYCELA [see Dosage and Administration (2.5)]. 

Dose reductions of RITUXAN HYCELA are not recommended. When RITUXAN HYCELA is given in combination with chemotherapy dose, reduce the chemotherapeutic drugs to manage adverse reactions.
The present invention relates to preparation of drug loaded heterogeneous nanosystems resulting from mixing of two monophasic phases, the non-aqueous phase comprising of active agent/s, polymers, lipids, surfactants, solubilizer/s and other excipients and the aqueous phase comprising of buffers, isotonic solutions, sweetners, flavors and other excipients.The novel technique enables formation of stable colloidal particles with high drug loading and predictable size at the time of use. The invention represents a major step in circumventing the technological challenges in the design of colloidal particles which can remain suspended for at least 4h maintaining an effective average particle size of <1μm. The unique delivery system makes part of the active agent/s readily bioavailable and part of the agent is present within the polymeric matrix. The invention is applicable to agent/s that contains electrical group, as the particles are formed due to electrostatic interaction. The novel technique avoids use of organic solvent and can reduce energy requirements compared to the conventional preparation methods. The invention is aimed at the overall improvement of therapeutic efficacy, enhance solubility, enhance oral bioavailability and rapid dissolution for in vivo delivery of the BCS class agent/s. The heterogeneous nanosystems /compositions produced according to the invention can be useful in drug delivery, imaging and diagnosis and can be administered by oral and parenteral route.
Patients will receive veltuzumab IV weekly for 4 doses and milatuzumab IV weekly on day 2 of week 1 and on day 4 of weeks 2-4 for 4 total doses during induction therapy. Patients may continue on therapy to receive extended induction therapy provided they do not experience significant toxicity or rapid disease progression during the initial 4 week induction.
This observational study will include adult US patients treated with andexanet alfa or 4F-PCC during a hospitalization for an anticoagulation-related major bleed. Data will be collected via an audit of electronic medical charts. The primary objectives are to describe the patients' characteristics, treatments and outcomes, including length of stay and in-hospital mortality. Secondary objectives include subgroup analyses, including by bleed location. Potential differences between patients treated with andexanet alfa versus 4F-PCC, and potential differences in patient characteristics over time, will be assessed. If this assessment confirms that treatment groups can be adequately balanced and that patient characteristics have not substantially changed over time (i.e. no channeling bias is observed), the risk of in-hospital mortality with andexanet alfa versus 4F-PCC will be assessed in a comparative effectiveness analysis. If treatment groups cannot be balanced or clear signs of channelling bias are observed, the comparative analyses will be considered unfeasible and will not be performed.
BACKGROUND: Numerous studies have revealed the role of dietary fatty acids in human health. However, few studies have evaluated dietary fatty acid patterns and their association with metabolic parameters. The current study aimed to explore the association between dietary fatty acid patterns and risk factors for metabolic syndrome (MetS) among overweight and obese adults.
METHODS: This cross-sectional study involved 340 participants who were overweight or obese. The study included assessments of body composition and anthropometric measurements. Dietary fatty acid consumption was evaluated using a validated Food Frequency Questionnaire (FFQ) containing 168 items. Additionally, biochemical parameters, including serum total cholesterol (TC), triglyceride (TG), high-density lipoprotein cholesterol (HDL-C), fasting serum glucose (FSG), and insulin levels, were measured using enzymatic methods. Fatty acid patterns were determined by principal component analysis (PCA), and the association between these dietary FA patterns and risk factors related to MetS components was assessed using logistic regression.
RESULTS: Factor analysis conducted in this study explored three dietary fatty acid patterns: saturated fatty acids (SFA), polyunsaturated fatty acids (PUFA), and long-chain combined fatty acids (LC-CFA). Those at the highest tertile of the SFA pattern had lower diastolic blood pressure (DBP) (P = 0.03). Low-density lipoprotein cholesterol (LDL) was lower in the second and third tertiles (P ≤ 0.05). Also, higher fasting blood glucose (FBS) was observed in the second and third tertiles (P < 0.05), and the homeostatic model assessment of insulin resistance (HOMA-IR) was higher in the third tertile (P = 0.049). In the PUFA pattern, FBS was lower in the third tertile (P = 0.03). In the LC-CFA pattern, lower TC was achieved in higher tertiles (P = 0.04).
CONCLUSION: Our findings demonstrated that consuming high and moderate SFA patterns is associated with higher FBS and HOMA-IR. Also, increased consumption of SCFAs is related to lower DPB and LDL. Individuals who consumed more PUFA, especially linoleic acid, had lower FBS. These outcomes might be beneficial in managing MetS and leading to a new field of research.
The data source for this study will be the Clinical Practice Research Database (CPRD) in the UK. New users of asenapine during the period following the UK marketing launch of asenapine will be identified in the CPRD. Use in Bipolar Disorder and other indications, as well as baseline demographic and physical characteristics, including prior health status, comorbidities, concomitant medications and healthcare resource utilization, will be described for the asenapine cohort, for participants aged 18 or greater. Use of asenapine in the general practice setting among pediatric participants will be described.

The primary comparison cohort will be aripiprazole. Participants in the aripiprazole cohort will be matched to participants treated with asenapine based on respective time after market entry. In addition, non-matched cohorts will be used to describe utilization of aripiprazole and other comparators.
In response to an alarming rise in active shooter/hostile incidents in the United States, in 2013 the American College of Surgeons convened a committee of multidisciplinary trauma experts who in collaboration with the federal government created a protocol for a national policy to enhance survivability from these active shooter incidents as well as other intentional mass casualty events. The committee's recommendations were called the Hartford Consensus. Among the recommendations of the Hartford Consensus was the training of first responders (law enforcement, EMS and fire personnel) as well as the public (so-called "immediate responders") in the basics of bleeding control. In October 2015, responding aforementioned recommendation, the White House launched the Stop the Bleed national awareness campaign as a "call to action". Under the auspices of the American College of Surgeons Committee on Trauma, a curriculum was developed teaching responders how to recognize and intervene in the event of catastrophic bleeding. Of the three bleeding control interventions promoted (external pressure, wound packing and tourniquet application) the tourniquet application component of the Stop the Bleed curriculum is evidence-based and provides the student with both didactic and psychomotor education. To date there is a paucity of data available to provide insight as to how long this vital skill is retained. More over there is no recommendation on refresher education with additional opportunities to practice this life-saving procedure. This study will serve as a follow-up to Stop the Bleed (also called Bleeding Control or B-Con) education provided by the investigator. The intent is to bring participants from a Bleeding Control course back to the investigator 6 months following initial education and assess their retention of tourniquet application skills. All participants will be assessed using a tourniquet simulator and their success will be measured in their ability to stop the bleeding using the simulator. The participants will be observed for proper identification of bleeding necessitating the use of a tourniquet, selection of the proper site of application, proper application of the device (use as described in the Stop the Bleed curriculum). This study will not involve the use of actual patients or human subjects. It is intended to be follow up assessment to skills-based education with an endpoint that will provide insight as to a time-frame for refresher training. Of the three bleeding control skills taught as part of the Stop the Bleed curriculum, the application the tourniquet is a universal stop the bleed intervention and most likely intervention to be used to stop the bleed.
Individuals and their families affected by disorders with a potentially genetic basis within six broad categories will be evaluated over time to characterize the natural and clinical history of various specific disorders. Medical and laboratory evaluations will be completed to identify areas of management concern that have not been previously described. Further protocols will be developed addressing specific disorders once a number of affected individuals have been investigated and is sufficient to query various aspects of those disorders. Issues for both diagnosis and medical management of those affected with certain genetic disorders will be collated and addressed within a national consensus conference format. In addition, phenotype to genotype correlation will be established to further understanding of specific molecular alterations on phenotypic expression. This broad-based protocol will also facilitate the training of fellows in medical genetics, graduate and post graduate training in genetics and genetic counseling.
PURPOSE:To obtain a perfume capable of lasting the fragrance for a long term with a weak irritant smell, by stirring a reodorant prepared by mixing and stirring D-benzylidenesorbitol and an alcohol containing dissolved hydroxypropyl cellose at a high rotational speed. CONSTITUTION:A reodorant is mixed with a very small amount, preferably 0.1-1wt%, D-benzylidenesorbitol and stirred at a high rotational speed for several tens of minutes. An alcohol is mixed with a small amount, preferably 1-5wt%, hydroxypropyl cellulose dissolved in an alcohol and stirred for several tens of minutes-several hours. The resultant reodorant and the alcohol are mixed and stirred for several tens of minutes-several hours at a high rotational speed, preferably 500-1,500r.p.m. for 30min-2hr, to give the aimed perfume. The irritant smell of the alcohol can be eliminated by sealing the alcohol mixture solution in a place in the absence of the ultraviolet light, and maturing the mixture solution with ultrasonic waves.
The participants in the intervention group will receive PFMT supervision in groups. The number of women per group and the detail of the intervention will be decided through stakeholder development group meetings.The intervention will be teaching the participants to do PFMT in groups. The intervention will help women to identify their pelvic floor muscles and then guide them how to contract the pelvic floor muscle correctly (the detail of the intervention will be discussed and determined in phase 1 of this project).
Peripheral alarm device for a patient monitoring system. In an embodiment, the peripheral alarm device includes an audio speaker and an audio detector. The peripheral alarm device also includes a control system that includes circuitry configured to communicate with the audio detector and a medical software program executed by a host computing system. The audio speaker is configured to generate an audible alarm in response to alarm instructions from the host computing system. The audio detector is configured to communicate a detection signal to the control system. The control system is configured to analyze the detection signal to verify whether the audible alarm was properly generated and communicate a control signal to the host computing system. The peripheral alarm device may include a light indicator and a light detector instead of the audio speaker and the audio detector or in addition to the audio speaker and the audio detector.